38 results
424B5
CNTA
Centessa Pharmaceuticals plc
13 Sep 24
Prospectus supplement for primary offering
4:02pm
complete, clinical trials;
our ability to identify screen, recruit and maintain a sufficient number of, or any, subjects in our existing … to advance our pipeline and product candidates into, and successfully complete, clinical trials;
our ability to identify screen, recruit
424B5
CNTA
Centessa Pharmaceuticals plc
11 Sep 24
Prospectus supplement for primary offering
4:40pm
to identify screen, recruit and maintain a sufficient number of, or any, subjects in our existing and anticipated studies or clinical trials including PRESent … pipeline and product candidates into, and successfully complete, clinical trials;
our ability to identify screen, recruit and maintain a sufficient number
S-3ASR
CNTA
Centessa Pharmaceuticals plc
11 Sep 24
Automatic shelf registration
4:01pm
screen, recruit and maintain a sufficient number of, or any, subjects in our existing and anticipated studies or clinical trials including PRESent-5
8-K
EX-99.1
CNTA
Centessa Pharmaceuticals plc
10 Sep 24
Regulation FD Disclosure
7:08am
and preclinical data related to ORX750; its ability to identify, screen, recruit and maintain a sufficient number of or any subjects in its existing … profile of our product candidates, including ORX750; whether
ORX750 could be shown to be ineffective; our ability to identify, screen and recruit
8-K
EX-99.1
92g4qod 0r6pfk
13 Aug 24
Centessa Pharmaceuticals Reports Financial Results and Business Highlights for Anticipated Upcoming Program Milestones
7:15am
8-K
EX-99.1
x81ch 3paummlu
10 Jun 24
Departure of Directors or Certain Officers
7:13am
8-K
EX-99.1
ydufdrmor8 pf3syn
13 May 24
Centessa Pharmaceuticals Reports Financial Results and Business Highlights for Anticipated Upcoming Program Milestones
4:23pm
424B5
eu2t68 ip
24 Apr 24
Prospectus supplement for primary offering
8:53pm
424B5
gu9rtj3
23 Apr 24
Prospectus supplement for primary offering
5:16pm
8-K
EX-99.1
0z4or0i
28 Mar 24
Centessa Pharmaceuticals Reports Business Highlights and Financial Results for the Fourth Quarter and Full-Year 2023
4:35pm
8-K
EX-99.1
kt1qi3uvx7skdw6xmlwa
9 Feb 24
Regulation FD Disclosure
7:12am
8-K
EX-99.2
mcqdfulb3rx4559hs
11 Dec 23
Regulation FD Disclosure
7:05am
8-K
EX-99.1
rwsc2mqoyfzf770u
13 Nov 23
Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the Third Quarter of 2023
4:17pm
8-K
EX-99.1
62lln3zpelp99cowb
14 Aug 23
Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the Second Quarter of 2023
7:06am
8-K
EX-99.1
oyvyc4
10 Jul 23
Regulation FD Disclosure
5:00pm